SLC5A2 and chronic kidney disease: Large placebo-controlled trials and meta-analyses have shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of kidney disease progression or cardiovascular death in a broad range of patients with chronic kidney disease (CKD) irrespective of diabetes status or levels of kidney function and albuminuria.1